SpringWorks: First and Only Treatment for Adults with Desmoid Tumors OKd

 Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life –

– SpringWorks to host conference call tomorrow at 8:00 a.m. ET –

SpringWorks will host a conference call and webcast to discuss the FDA approval of OGSIVEO on Tuesday, November 28, 2023, at 8:00 a.m. ET. To join the live webcast and view the corresponding slides, please click here. To access the live call by phone, please pre-register for the call here. Once registration is complete, participants will be provided with a dial-in number and conference code to access the call. A replay of the webcast will be available for a limited time following the event on the Investors and Media section of the Company’s website at https://ir.springworkstx.com.

https://www.globenewswire.com/news-release/2023/11/27/2786554/0/en/SpringWorks-Therapeutics-Announces-FDA-Approval-of-OGSIVEO-nirogacestat-as-the-First-and-Only-Treatment-for-Adults-with-Desmoid-Tumors.html